Healthcare Services company Suraksha Diagnostic announced Q2FY26 results Total Income: Rs 795.80 million against Rs 680.67 million during Q2FY25, change 16.9%. EBTIDA: Rs 249.66 million against Rs 245.07 million during Q2FY25, change 1.9%. EBTIDA Margin: 31.7% for Q2FY26. PAT: Rs 88.28 million against Rs 101.56 million during Q2FY25, change -13.1%. PAT Margin: 11.2% for Q2FY26. Ritu Mittal, Joint Managing Director & CEO, said: “Suraksha reported another quarter of strong top-line growth, driven primarily by test volumes. The QoQ andYoY total revenue growth was 8.3% and 16.9%, respectively. I am happy to announce that we have added 11 centres in H1FY26. We are working on 3 hub centres and 6spoke centres, which will be operational in the second half of FY26, which will take the total count to 20 for theyear. In Q1FY26, we launched Suraksha Genomics, a dedicated vertical offering cutting-edge genetic and moleculartesting services. The lab is now fully operational and we expect to leverage the same to drive future growth. As the new centres mature, their margin contributions will increase, moving overall performance closer toindustry benchmarks and supporting improved profitability across our network. We remain committed to creating value for our shareholders, driven by innovation, operational excellence andsustainable growth.” Result PDF